This comparison further highlights the significant up-regulation of well-established markers of DNA damage response (CDKN1A/p21, MDM2), liver fibrosis (e.g., AhR), liver hyperplasia (e.g., CYP1A1) and liver inflammation (e.g., BCL6) in response to genotoxic carcinogens, and the up-regulation of markers of liver steatosis, (e.g., CYP4A11, DECR1, EHHADH) and hepatocellular peroxisome proliferation (e.g., ACOX1) in response to non-genotoxic carcinogens. This evidence concerns the gene BCL6 and Hepatic fibrosis.